Fatal narcotics at the centre of a coroner’s inquest were found by university students in a glass vial, a container so unusual for street drugs that a police officer said it resembled a ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Fatal narcotics at the centre of a coroner’s inquest were found by university students in a glass vial, a container so unusual for street drugs that a police officer said it resembled a ...

Attorney General Pam Bondi revealed that she carries around a vial of fake fentanyl to show that just a tiny amount can kill, while warning parents of the “monsters” their children may be ...

Johnson & Johnson today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These ...

72% of patients were in clinical remission b with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92. 43% of patients were in endoscopic remission. c Among ...

Key drugs Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound now account for $7.5 billion of Lilly’s revenue. With a significant pipeline in various stages of the drug ...

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO ...

"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...

Jimmy McMahon and Connor Ritter each had two RBI for Glassboro, collected two hits each and combined to score three runs. Alex Paz drove in Juan Feliciano with an RBI-double in the top of the ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...